CODEN: WJAPAC Impact Factor: 5.48 ISSN: 3049-3013

World Journal of Advance Pharmaceutical Sciences

Volume 3, Issue 3, Page: 50-64 Review Article www.wjaps.com

MOLECULAR HEMATOLOGY OF CHRONIC MYELOID LEUKEMIA: RECENT ADVANCES IN PATHOGENESIS, DIAGNOSIS AND TARGETED THERAPIES – AN UPDATED REVIEW

Gamal Abdul Hamid*[1,2], Samira A. Abdul Rahman[2]

[1]National Oncology Center, Aden.
[2]Faculty of Medicine and Health Sciences, University of Aden.

How to cite this Article: Gamal Abdul Hamid, Samira A. Abdul Rahman. (2026). MOLECULAR HEMATOLOGY OF CHRONIC MYELOID LEUKEMIA: RECENT ADVANCES IN PATHOGENESIS, DIAGNOSIS AND TARGETED THERAPIES – AN UPDATED REVIEW. World Journal of Advance Pharmaceutical Sciences, 3(3), 50-64.

Article Info

Article Received: 16 January 2026,

Article Revised: 06 February 2026,

Article Accepted: 26 February 2026.

DOI: https://doi.org/10.5281/zenodo.18818080

***Corresponding author:**

Prof. Dr. Gamal Abdul Hamid

National Oncology Center, Aden.

ABSTRACT

Background: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion oncogene, resulting from the reciprocal translocation t(9;22)(q34;q11.2). The development of tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 has revolutionized CML therapy, transforming a once-fatal disease into a manageable chronic condition with near-normal life expectancy. **Objective:** This comprehensive review synthesizes recent advances in the molecular pathogenesis, diagnostic approaches, therapeutic strategies, and emerging challenges in CML management, with a focus on developments from 2020-2025. **Methods:** We conducted a systematic review of peer-reviewed literature from PubMed, Scopus, and Web of Science databases, emphasizing clinical trials, consensus guidelines, and molecular studies published between 2000-2025. **Results:** Six TKIs are currently approved for CML treatment: imatinib (first-generation), dasatinib, nilotinib, bosutinib (second-generation), and ponatinib and asciminib (third-generation). Frontline therapy achieves 10-year overall survival rates of 82-87% and relative survival of 90-95%. Treatment-free remission (TFR) is achievable in 40-60% of patients with sustained deep molecular response (DMR) for ≥2 years, with TFR rates reaching 80-85% after ≥5 years of DMR. Resistance mechanisms include BCR::ABL1 kinase domain mutations (notably T315I), clonal evolution, and BCR::ABL1-independent pathways. The T315I "gatekeeper" mutation confers resistance to all first- and second-generation TKIs but is sensitive to ponatinib and asciminib. Cardiovascular toxicity remains a significant concern with second- and third-generation TKIs, particularly nilotinib and ponatinib. Emerging third-generation TKIs (olverembatinib, TGRX-678, TERN-701, ELVN-001) show promising efficacy in resistant disease. **Conclusion:** The molecular era has established precision medicine for CML, with ongoing research focused on overcoming resistance, increasing TFR rates, managing long-term toxicities, and ensuring global access to effective therapies.

KEYWORDS: chronic myeloid leukemia, BCR-ABL1, tyrosine kinase inhibitors, treatment-free remission, T315I mutation, molecular monitoring, targeted therapy, resistance mechanisms.

1. INTRODUCTION

1.1 Epidemiology and Global Burden

Chronic Myeloid Leukemia (CML) is a clonal hematopoietic stem cell disorder with an annual incidence of 1.0-2.0 cases per 100,000 population, accounting for approximately 15-20% of all adult leukemias.[1,2] In the United States, an estimated 9,600 new cases were diagnosed in 2024, with a median age at diagnosis of 64 years and a slight male predominance (1.3:1 male-to-female ratio).[3,4]

The introduction of tyrosine kinase inhibitors (TKIs) has dramatically altered CML epidemiology. Before the TKI era, annual mortality was 10-20%; today, it is approximately 1%.[5] Consequently, CML prevalence in the United States has increased from approximately 30,000 cases in 2000 to an estimated 150,000 cases in 2025.[6] Worldwide prevalence is projected to reach approximately 5 million cases, highlighting the critical need for affordable, accessible therapies globally.[7]

1.2 Historical Milestones

The molecular understanding of CML represents a landmark achievement in oncology. In 1960, Nowell and Hungerford first described the Philadelphia (Ph) chromosome, establishing the first association between a specific chromosomal abnormality and human cancer.[8] Rowley's 1973 discovery of the reciprocal t(9;22)(q34;q11.2) translocation provided the cytogenetic foundation[9], while cloning of the BCR::ABL1 fusion gene in the 1980s revealed the molecular basis for targeted therapy.[10]

The approval of imatinib mesylate in 2001 revolutionized CML treatment and inaugurated the era of targeted cancer therapy.[11] Druker and colleagues demonstrated unprecedented efficacy, with complete cytogenetic response rates exceeding 75% and minimal toxicity compared to conventional chemotherapy.[12] This breakthrough transformed CML from a uniformly fatal disease to a manageable chronic condition.

1.3 Clinical Impact and Current Challenges

Modern TKI therapy has achieved remarkable outcomes: 10-year overall survival rates of 82-87% and relative survival approaching that of age-matched controls.[13,14] The German CML IV study, involving 1,551 patients treated with imatinib-based regimens, documented 10-year cumulative major molecular response (MMR) rates of 90%, deep molecular response (DMR) rates of 80%, and blastic phase transformation incidence of only 5.8%.[15]

Despite these advances, significant challenges persist. TKI resistance affects 5-10% of patients, with annual resistance rates of approximately 1%.[16] The T315I "gatekeeper" mutation confers resistance to all first- and second-generation TKIs.[17] Long-term cardiovascular toxicity, particularly with nilotinib and ponatinib, has emerged as a major concern.[18] Treatment-free remission (TFR), while achievable in 40-60% of patients with sustained DMR, remains elusive for many.[19] Additionally, global disparities in TKI access and affordability continue to limit outcomes in resource-constrained settings.[20]

1.4 Review Objectives

This comprehensive review synthesizes recent advances in CML molecular hematology, focusing on:

- Updated pathogenesis and molecular mechanisms
- Contemporary diagnostic approaches and monitoring strategies
- Current therapeutic landscape and TKI selection algorithms
- Resistance mechanisms and management strategies
- Treatment-free remission and emerging therapeutic paradigms
- Future directions and unanswered questions

2. MOLECULAR PATHOGENESIS

2.1 The BCR::ABL1 Fusion Oncogene

CML originates from a pluripotent hematopoietic stem cell acquiring the reciprocal translocation t(9;22)(q34;q11.2), generating the Philadelphia chromosome and the BCR::ABL1 fusion gene.[21] This chimeric oncogene encodes a constitutively active tyrosine kinase that drives malignant transformation through multiple downstream signaling pathways.[22]

2.1.1 Breakpoint Cluster Regions and Transcript Variants

The breakpoints in chromosome 22 localize to three distinct breakpoint cluster regions (BCRs), determining the amount of BCR retained in the fusion transcript[23]:

- **Major BCR (M-bcr):** Breakpoints between exons e12-e16 (formerly b1-b5) generate e13a2 (b2a2) or e14a2 (b3a2) fusion mRNAs, encoding the p210 BCR::ABL1 oncoprotein. These transcripts account for >95% of CML cases.[24]
- **Minor BCR (m-bcr):** Breakpoints between exons e1-e2 generate e1a2 fusion mRNA, encoding the p190 BCR::ABL1 oncoprotein. While common in Ph-positive acute lymphoblastic leukemia (ALL), p190 occurs in only 1-2% of CML cases and may be associated with more aggressive disease.[25,26]
- **Micro BCR (μ-bcr):** Breakpoints between exons e19-e20 generate e19a2 fusion mRNA, encoding the p230 BCR::ABL1 oncoprotein. This rare variant (<1%) is associated with an indolent course resembling chronic neutrophilic leukemia.[27]

Approximately 1-2% of patients harbor atypical transcripts (e13a3, e14a3, e1a3) that may yield false-negative results with standard PCR assays, necessitating multiplex testing at diagnosis.[28]

2.1.2 Structural and Functional Consequences

BCR::ABL1 exhibits constitutive tyrosine kinase activity due to disruption of the autoinhibitory conformation maintained in normal ABL1.[29] The BCR moiety

contributes oligomerization domains that promote autophosphorylation, while the ABL1 kinase domain remains constitutively active.[30] This results in:

- Loss of cell cycle regulation
- Reduced apoptosis
- Altered adhesion to stromal cells and extracellular matrix
- Genomic instability

2.2 Downstream Signaling Pathways

BCR::ABL1 activates multiple signaling cascades that collectively produce the leukemic phenotype[31]:

2.2.1 RAS/MAPK Pathway

BCR::ABL1 constitutively activates the RAS/RAF/MEK/ERK pathway through GRB2 and SOS adaptor proteins, promoting proliferation and survival.[32] ERK1/2 activation enhances transcription of genes involved in cell cycle progression and inhibits pro-apoptotic proteins.

2.2.2 PI3K/AKT/mTOR Pathway

Phosphatidylinositol-3 kinase (PI3K) activation generates PIP3, recruiting AKT to the membrane where it is phosphorylated and activated.[33] AKT promotes survival through phosphorylation of BAD, inhibition of FOXO transcription factors, and activation of mTOR, which regulates protein synthesis and cell growth.

2.2.3 JAK/STAT Pathway

BCR::ABL1 activates JAK2 and STAT5, with STAT5 directly promoting transcription of anti-apoptotic genes including BCL-XL.[34] STAT5 activation is critical for leukemogenesis and maintaining the malignant phenotype.

2.2.4 NF-κB Pathway

Constitutive NF-κB activation contributes to survival and resistance to apoptosis through transcriptional upregulation of multiple anti-apoptotic genes.[35]

2.3 Clonal Evolution and Disease Progression

Without effective therapy, CML invariably progresses from chronic phase (CP) through accelerated phase (AP) to blastic phase (BP), an acute leukemia of myeloid (50-80%) or lymphoid (20-30%) phenotype.[36]

2.3.1 Additional Chromosomal Abnormalities

Clonal cytogenetic abnormalities in Ph-positive cells (CCA/Ph+) occur in 70-80% of BP-CML cases and may herald disease progression.[37] High-risk abnormalities include:

- i(17)(q10) – loss of TP53 tumor suppressor
- Trisomy 8 (+8)
- +Ph (duplicate Philadelphia chromosome)
- Trisomy 19 (+19)
- -7/del7q
- 3q26.2 rearrangements (MECOM) – median overall survival <1 year.[38]

2.3.2 Somatic Mutations

Cancer-related gene mutations are detected in 10-18% of newly diagnosed CML patients, most commonly ASXL1 (8%), with DNMT3A, IDH1/2, EZH2, and TET2 occurring less frequently.[39] ASXL1 mutations predict:

- Inferior molecular response rates
- Higher treatment failure rates
- Increased acquisition of kinase domain mutations
- Recurrent cytopenias during TKI therapy.[40,41]

2.3.3 Epigenetic Dysregulation

Progression to BP-CML involves complex epigenetic alterations, including reduced activity of polycomb repressive complex 2 (PRC2) and upregulation of PRC1 components.[42] These changes converge on a relatively uniform epigenetic pattern despite heterogeneous upstream mutations.

3. DIAGNOSIS AND MONITORING

3.1 Diagnostic Approach

3.1.1 Clinical Presentation

In developed countries, 50-60% of patients are diagnosed incidentally during routine health maintenance.[43] Symptomatic patients typically present with:

- Fatigue, malaise, weight loss (anemia-related)
- Left upper quadrant fullness or pain (splenomegaly)
- Early satiety
- Less commonly: priapism, visual disturbances, thrombotic events

In resource-constrained settings, high-risk CML at presentation may reach 25-40%, with massive splenomegaly, significant leukocytosis, and constitutional symptoms.[44]

3.1.2 Laboratory Evaluation

Complete blood count typically reveals:

- Leukocytosis (often >50 × 10^9/L)
- Left-shifted granulopoiesis with full spectrum of precursors
- Basophilia (pathognomonic finding)
- Thrombocytosis (common)
- Mild anemia (frequent)

Peripheral blood smear demonstrates myelocytes, metamyelocytes, and occasional blasts (<10% in CP). Basophilia and eosinophilia may be present.[45]

3.1.3 Bone Marrow Examination

Bone marrow aspirate and biopsy reveal:

- Hypercellular marrow with myeloid predominance
- Left-shifted granulopoiesis
- Abnormally small, non-lobated megakaryocytes (micromegakaryocytes)
- Pseudo-Gaucher cells (macrophages with foamy cytoplasm)
- Reticulin fibrosis (grade 1-2) in some cases.[46]

Bone marrow evaluation at diagnosis provides accurate blast percentage, basophil count, and assessment of additional chromosomal abnormalities.[47]

3.2 Cytogenetic and Molecular Diagnostics

3.2.1 Conventional Cytogenetics

Metaphase karyotyping of bone marrow cells (minimum 20 metaphases) confirms Ph chromosome positivity in >95% of CML patients.[48] Complex translocations involving additional chromosomes occur in 3-5% but do not impact prognosis on TKI therapy.[49]

3.2.2 Fluorescence In Situ Hybridization (FISH)

FISH on interphase nuclei increases sensitivity, allowing analysis of 200-500 nuclei.[50] Advantages include:

- Detection of cryptic BCR::ABL1 rearrangements
- Identification of deletions adjacent to breakpoints
- Useful for monitoring atypical transcripts not detected by standard PCR.[51]

3.2.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Qualitative RT-PCR identifies BCR::ABL1 fusion mRNA and establishes the specific transcript type.[52] Quantitative RT-PCR (qRT-PCR) with International Scale (IS) standardization enables precise monitoring of molecular response.[53]

A value of 100% on IS represents the average BCR::ABL1 mRNA expression of 30 patients from the IRIS study baseline. Fold reductions include:

- MMR (MR3): ≤0.1% IS (3-log reduction)
- MR4: ≤0.01% IS (4-log reduction)
- MR4.5: ≤0.0032% IS (4.5-log reduction).[54]

3.2.4 Droplet Digital PCR (ddPCR)

Emerging evidence supports ddPCR as more accurate than RT-PCR for predicting TFR success, particularly in patients with undetectable disease by conventional methods.[55] A ddPCR threshold of 0.468 BCR::ABL1 copies/mL predicted 83% TFR at 2 years versus 52% for higher levels.[56]

3.3 Response Definitions and Milestones

Table 1 summarizes standardized response definitions according to ELN 2020 recommendations.[57]

Table 1: Response Definitions in CML.

Response Category	Definition
Complete Hematologic Response (CHR)	Normalization of blood counts, no blasts or promyelocytes, no splenomegaly
Complete Cytogenetic Response (CCyR)	0% Ph+ metaphases (≥20 metaphases)
Major Cytogenetic Response (MCyR)	0-35% Ph+ metaphases
Major Molecular Response (MMR/MR3)	BCR::ABL1 ≤0.1% IS
Deep Molecular Response (DMR)	MR4 (≤0.01% IS) or MR4.5 (≤0.0032% IS)
Molecular Relapse	Loss of MMR (BCR::ABL1 >0.1% IS) on two consecutive tests

3.3.1 Optimal Response Milestones

- **3 months:** BCR::ABL1 ≤10% IS (early molecular response)
- **6 months:** BCR::ABL1 ≤1% IS
- **12 months:** BCR::ABL1 ≤0.1% IS (MMR)
- **15-18 months:** BCR::ABL1 ≤0.01% IS (MR4).[58]

Achievement of early molecular response (<10% at 3 months) strongly correlates with improved progression-free and overall survival.[59]

4. TYROSINE KINASE INHIBITOR THERAPY

4.1 Currently Approved TKIs

Six TKIs are currently approved for CML treatment (Table 2).[60]

Table 2: Approved Tyrosine Kinase Inhibitors for CML.

Generation	Drug	Standard Dose	Key Indications	Notable Adverse Effects
First	Imatinib	400 mg daily	Frontline CML-CP	Edema, nausea, myalgias, cytopenias
Second	Dasatinib	100 mg daily (50 mg alternative)	Frontline CML-CP, post-imatinib	Pleural effusion, pulmonary hypertension, bleeding
Second	Nilotinib	300 mg twice daily	Frontline CML-CP, post-imatinib	QTc prolongation, pancreatitis, hyperglycemia, arterial

				occlusive events
Second	Bosutinib	400 mg daily	Frontline CML-CP, post-imatinib	Diarrhea, hepatotoxicity, renal impairment
Third	Ponatinib	45 mg daily (reduce to 15 mg upon response)	T315I mutation, multi-TKI failure	Cardiovascular events, thrombosis, hepatotoxicity
Third (STAMP)	Asciminib	80 mg daily (frontline) 40 mg BID (T315I)	Frontline CML-CP, post-2 TKIs, T315I	Hypertension, lipase elevation, cardiovascular events

4.1.1 First-Generation TKI: Imatinib

Imatinib 400 mg daily revolutionized CML therapy. The IRIS study demonstrated imatinib's superiority over interferon-α plus cytarabine, with 10-year follow-up confirming durable responses.[61] The German CML IV study (1,551 patients) documented:

- 10-year cumulative MMR: 90%
- 10-year DMR: 80%
- 10-year OS: 82%
- 10-year relative survival: 92%
- Annual resistance rate: 1%.[15]

4.1.2 Second-Generation TKIs

Dasatinib: The DASISION trial compared dasatinib 100 mg daily versus imatinib in newly diagnosed CML-CP.[62] At 5 years:

- MMR: 76% vs. 64% ($p<0.05$)
- CCyR: 86% vs. 82%
- 5-year OS: 91% vs. 90%

Pleural effusion occurred in 25% of dasatinib-treated patients, with pulmonary hypertension in <2%.[63]

Nilotinib: The ENESTnd trial demonstrated nilotinib 300 mg twice daily superiority over imatinib.[64] At 10 years:

- MMR: 78% vs. 63%
- Progression-free survival: 86% vs. 87%
- OS: 88% vs. 88%

Cardiovascular adverse events affected 25-35% of nilotinib-treated patients at 10 years, including peripheral arterial occlusive disease, myocardial infarction, and stroke.[65]

Bosutinib: The BFORE trial established bosutinib 400 mg daily frontline efficacy.[66] At 5 years:

- MMR: 74% vs. 65%
- CCyR: 83% vs. 77%
- OS: 95% vs. 95%

Gastrointestinal toxicity (diarrhea) is common but often self-limited with dose escalation strategies.[67]

4.1.3 Third-Generation TKIs

Ponatinib: Designed to overcome T315I mutation through carbon-carbon triple bond that bypasses the gatekeeper residue.[68] The PACE trial in resistant/intolerant patients demonstrated:

- 5-year OS: 73% (CP-CML)
- Major cytogenetic response: 55%
- MMR: 40%.[69]

Cardiovascular toxicity (arterial occlusive events, venous thromboembolism) occurs in 25-35%, necessitating dose reduction to 15 mg once response achieved (BCR::ABL1 <1%).[70]

Asciminib: First STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, stabilizing BCR::ABL1 in inactive conformation.[71] The ASC4FIRST trial compared asciminib 80 mg daily versus investigator-choice TKI in frontline CML-CP[72]:

- 12-month MMR: 68% vs. 49% ($p<0.001$)
- vs. imatinib: 69% vs. 40% ($p<0.001$)
- vs. 2G TKI: 66% vs. 58% (p=NS)

The ASCEMBL trial in patients failing ≥2 prior TKIs showed asciminib 40 mg twice daily superior to bosutinib:

- 24-week MMR: 25.5% vs. 13.2%.[73]

4.2 Frontline TKI Selection

Four aims guide frontline TKI selection in 2025[74]:

1. Normalize patient lifespan (achieved with all approved TKIs)
2. Achieve durable DMR enabling TFR
3. Minimize short- and long-term toxicities
4. Provide good treatment value

4.2.1 Patient Age

- **Younger patients (<60 years):** Earlier durable DMR and TFR may justify 2G TKI or asciminib to maximize TFR potential.[75]
- **Older patients (≥60 years):** Generic imatinib provides excellent survival with manageable toxicity.[76]

4.2.2 Comorbidities

- **Avoid dasatinib:** Chronic pulmonary disease, pulmonary hypertension.
- **Avoid nilotinib:** Diabetes, cardiovascular disease, pancreatitis history
- **Avoid bosutinib:** Pre-existing gastrointestinal, hepatic, or renal dysfunction.[77]

4.2.3 Risk Stratification

- **Low/intermediate Sokal/ELTS:** Comparable outcomes with all TKIs
- **High-risk:** 2G TKI may be preferred (improved MMR/DMR rates, trend toward reduced progression).[78]

4.2.4 Cost Considerations

Generic imatinib (<$500/year) offers optimal treatment value. Generic dasatinib ($4,000-7,000/year) provides cost-effective 2G TKI option. Novel TKIs (>$200,000/year) require careful value assessment.[79]

4.3 TKI Dose Optimization

Emerging evidence supports optimal biologic dose (OBD) rather than maximum tolerated dose (MTD) for long-term therapy.[80] Dose reduction strategies maintain efficacy while reducing toxicity (Table 3).[81]

Table 3: TKI Dose Reduction Strategies.

TKI	Standard Dose	Reduced Dose	Indication
Imatinib	400 mg daily	100-300 mg daily	Grade 3-4 toxicity, stable MR2/MR3+
Dasatinib	100 mg daily	20-50 mg daily	Pleural effusion, cytopenias
Nilotinib	300 mg BID	150-200 mg BID	Cardiovascular risk, cytopenias
Bosutinib	400 mg daily	100-300 mg daily	Gastrointestinal toxicity, cytopenias
Ponatinib	45 mg daily	15 mg daily (after BCR::ABL1 <1%)	Cardiovascular risk reduction

Dasatinib 50 mg daily frontline achieves comparable efficacy to 100 mg with significantly reduced pleural effusion risk.[82] Intermittent TKI schedules (1 month on/1 month off) and progressive dose de-escalation improve quality of life without compromising outcomes in selected elderly patients.[83]

5. RESISTANCE MECHANISMS AND MANAGEMENT

5.1 Epidemiology of TKI Resistance

Treatment resistance (BCR::ABL1 >1% after 12 months, loss of response, or progression) occurs in approximately 5-10% of patients, with annual resistance rate of 1%.[84]

5.2 BCR::ABL1-Dependent Resistance

5.2.1 Kinase Domain Mutations

Mutations in the BCR::ABL1 kinase domain represent the most common mechanism of acquired resistance (50-60% of imatinib failure cases).[85] Over 100 mutations have been described, affecting:

- ATP binding loop (P-loop): E255K, Y253H, G250E
- Gatekeeper residue: T315I
- Activation loop: F359V, H396R

5.2.2 The T315I Gatekeeper Mutation

T315I (threonine to isoleucine at position 315) confers resistance to all first- and second-generation TKIs by:

- Disrupting critical hydrogen bond with inhibitors
- Restricting access to hydrophobic pocket.[86]

Ponatinib and asciminib retain activity against T315I.[87] For T315I-positive CML:

- Ponatinib 45 mg daily (reduce to 15 mg upon response)
- Asciminib 200 mg twice daily
- Olverembatinib 40 mg every other day.[88]

5.2.3 Compound Mutations

Subclones may acquire second mutations in the same BCR::ABL1 allele, creating compound mutations conferring high-level resistance to most/all approved TKIs.[89]

5.2.4 BCR::ABL1 Overexpression

Gene amplification or transcriptional upregulation increases BCR::ABL1 levels, overcoming TKI inhibition.[90]

5.2.5 Drug Influx/Efflux

Reduced organic cation transporter-1 (OCT-1) activity impairs imatinib uptake.[91] ABCB1 (MDR1) and ABCG2 (BCRP) efflux pump overexpression protects leukemic cells.[92]

5.3 BCR::ABL1-Independent Resistance

Multiple pathways maintain cell survival despite effective BCR::ABL1 kinase inhibition[93]:

- PI3K/AKT/mTOR pathway activation
- JAK/STAT pathway signaling through alternative mechanisms
- LYN and HCK kinase activation
- Microenvironment-mediated protection

5.4 Management of TKI Resistance

5.4.1 Diagnostic Approach

Patients with inadequate response or loss of response require:

- Compliance assessment

- Drug interaction review
- Bone marrow aspirate/biopsy
- Metaphase karyotyping
- BCR::ABL1 kinase domain mutation screen (preferably NGS).[94]

5.4.2 Mutation-Guided TKI Selection

Table 4 summarizes TKI sensitivity based on BCR::ABL1 mutations.[95]

Table 4: Mutation-Guided TKI Selection.

Mutation	Sensitive TKIs	Resistant TKIs
T315I	Ponatinib, Asciminib, Olverembatinib	Imatinib, Dasatinib, Nilotinib, Bosutinib
Y253H, E255K/V	Dasatinib, Bosutinib (variable)	Imatinib, Nilotinib
F359V/C/I	Dasatinib, Bosutinib	Imatinib, Nilotinib
V299L	Imatinib, Nilotinib	Dasatinib, Bosutinib
F317L	Imatinib, Nilotinib	Dasatinib, Bosutinib
G250E	Dasatinib	Imatinib, Nilotinib, Bosutinib
L248V	-	Imatinib, Nilotinib, Bosutinib

5.4.3 Sequential TKI Therapy

- **Imatinib failure (no mutation):** Dasatinib, nilotinib, or bosutinib produce CCyR rates ~50%, 6-year OS ~70%.[96]
- **2G TKI failure (no guiding mutation):** Rotating to another 2G TKI yields low response rates (CCyR ~20%)
- **Multi-TKI failure:** Ponatinib or asciminib achieve MMR rates 40-50%, 5-year OS >70%.[97]

5.4.4 Novel Third-Generation TKIs

Olverembatinib: Approved in China for T315I-mutated CML.[98] Phase 1/2 study (165 patients, 83% T315I+) demonstrated:

- 3-year CCyR: 69% (CP-CML)
- 3-year MMR: 56%
- MR4: 44%, MR4.5: 39%.[99]

Registrational phase 2 study versus best available therapy:

- CCyR: 36.4% vs. 16.2%
- MMR: 27.3% vs. 8.1%
- 2-year EFS: 46.9% vs. 16.9% ($p<0.001$).[100]

TGRX-678, TERN-701, ELVN-001: STAMP inhibitors in clinical development for resistant CML, demonstrating early efficacy and tolerability.[101,102]

5.5 Allogeneic Hematopoietic Stem Cell Transplantation

HSCT remains curative for CML but is utilized infrequently in the TKI era (<10% of patients).[103] Indications include:

- Progression to AP/BP-CML (after achieving second CP)
- T315I mutation with inadequate response to ponatinib/asciminib
- MECOM rearrangement (3q26.2) – median OS <1 year without HSCT
- Failure of ≥2 TKIs, particularly with ASXL1 mutations.[104]

HSCT is underutilized despite curative potential and cost-effectiveness compared to lifelong novel TKI therapy.[105]

6. TREATMENT-FREE REMISSION

6.1 Historical Development

The STIM (Stop Imatinib) trial first demonstrated TFR feasibility in 2010.[106] Patients with sustained complete molecular response (undetectable BCR::ABL1) for ≥2 years discontinued imatinib, with 12-month molecular recurrence-free survival of 41%.[107]

6.2 TFR Criteria

Current TFR eligibility criteria[108]:

- Age ≥18 years
- TKI therapy duration ≥3 years
- Sustained DMR (MR4 or better) for ≥2 years
- Chronic phase CML (no prior AP/BP)
- Access to reliable qPCR monitoring
- Good compliance history

6.3 TFR Outcomes

6.3.1 TFR Rates by DMR Duration

- **DMR 2+ years:** TFR 40-50%.[109]
- **DMR 5+ years:** TFR 80-85%.[110]
- **TKI therapy 10+ years + sustained DMR:** TFR approaching 90%.[111]

6.3.2 Predictors of Successful TFR

- Longer TKI therapy duration
- Longer DMR duration
- e14a2 transcript (vs. e13a2) in some studies.[112]
- Higher NK cell counts, lower T regulatory cells.[113]

- TKI withdrawal syndrome (musculoskeletal pain, flushing).[114]

6.3.3 TFR After Second-Generation TKIs

Multiple studies confirm similar TFR rates (40-60%) with dasatinib, nilotinib, and bosutinib discontinuation.[115-118] Faster DMR achievement with 2G TKIs may increase TFR-eligible patients but not TFR rates.[119]

6.4 Post-Discontinuation Monitoring

Recommended monitoring schedule[120]:

- **Year 1:** Monthly PCR
- **Year 2:** Every 2-3 months
- **Year 3+:** Every 3-4 months, then every 4-6 months

Molecular relapse (loss of MMR confirmed on two tests) prompts TKI re-initiation, with >90% regaining response.[121]

6.5 TKI Withdrawal Syndrome

Approximately 25% of patients develop musculoskeletal pain, arthralgias, and flushing after TKI discontinuation.[122] Management:

- NSAIDs for mild symptoms
- Short course oral steroids for moderate symptoms
- Rarely requires TKI re-initiation

Interestingly, TKI withdrawal syndrome correlates with higher TFR success.[123]

7. ADVANCED PHASE CML

7.1 Classification and Incidence

CML-AP and CML-BP affect 5-10% of patients at diagnosis or during treatment.[124] The 2022 WHO classification eliminated CML-AP, but AP features developing during therapy retain poor prognosis (median OS ~3 years).[125,126]

7.2 De Novo Accelerated Phase

Patients presenting with AP features achieve improved outcomes with 2G TKI therapy:

- 8-year OS: 60-80%
- Requires close monitoring and consideration for HSCT.[127]

7.3 Blastic Phase Management

7.3.1 Induction Therapy

- **Myeloid BP:** TKI (ponatinib preferred) + hypomethylating agent (azacitidine/decitabine) ± venetoclax.[128]
- **Lymphoid BP:** TKI + hyper-CVAD or ALL-type induction.[129]
- Goal: Achieve second CP as bridge to HSCT

7.3.2 Post-Remission Therapy

- Allogeneic HSCT once second CP achieved
- TKI maintenance post-HSCT for 3-5 years based on tolerability.[130]

8. TOXICITY MANAGEMENT

8.1 Cardiovascular Toxicity

8.1.1 Nilotinib

- Arterial occlusive events (peripheral arterial disease, MI, CVA) in 25-35% at 10 years.[131]
- Mechanisms: Impaired glucose tolerance, dyslipidemia, accelerated atherosclerosis
- Avoid in patients with cardiovascular risk factors

8.1.2 Ponatinib

- Cardiovascular events in 25-35%.[132]
- Mechanisms: VEGF, PDGFR, TIE2 inhibition; VWF-mediated platelet adhesion.[133]
- Dose-dependent toxicity: reduce to 15 mg once BCR::ABL1 <1%

8.1.3 Dasatinib

- Pleural effusion (25%), pulmonary hypertension (<2%).[134]
- Avoid in chronic pulmonary disease

8.1.4 Asciminib

- Early data suggest cardiovascular events (hypertension, coronary disease) in <5%.[135]
- Longer follow-up needed.

8.2 Non-Cardiovascular Toxicities

8.2.1 Hematologic

Cytopenias occur with all TKIs, often improving with dose reduction or supportive care.[136]

8.2.2 Gastrointestinal

- Bosutinib: Diarrhea (80-90%, usually self-limited with dose escalation)
- Imatinib: Nausea, vomiting (manage with antiemetics, food)

8.2.3 Hepatic

- Transaminase elevations (bosutinib, ponatinib, asciminib)
- Monitor LFTs regularly

8.2.4 Renal

- Bosutinib: Renal impairment (monitor Cr)
- Nilotinib: Preferred for reduced GFR.[137]

8.2.5 Pancreatic

- Lipase elevation (nilotinib, asciminib)
- Clinical pancreatitis (any TKI) – discontinue offending agent

8.2.6 Immune-Mediated

- Pneumonitis, pericarditis, hepatitis, nephritis
- Respond to short course steroids.[138]

8.3 Cross-Intolerance

Patients intolerant to one TKI have increased risk of intolerance to others (different or same toxicity).[139] Manage with:

- Dose reduction before switching
- Careful monitoring after switch

9. SPECIAL POPULATIONS

9.1 Pregnancy

- TKIs contraindicated (teratogenic)
- Interferon-α safest option for disease control.[140]
- TKI discontinuation in stable DMR with close monitoring

9.2 Elderly Patients

- Generic imatinib provides excellent outcomes
- Dose reduction for toxicity
- Consider TFR less urgent.[141]

9.3 Pediatric CML

- Imatinib approved for pediatric use
- 2G TKIs increasingly studied.[142]

9.4 COVID-19

- CML patients with high-risk factors (advanced phase, no CHR, comorbidities) have increased COVID-19 risk.[143]
- Vaccination strongly recommended
- TKI continuation generally safe.[144]

10. GLOBAL HEALTH CONSIDERATIONS

10.1 Prevalence and Access

Worldwide CML prevalence estimated at 5 million cases by 2025.[145] Disparities in TKI access persist:

- High-income countries: All TKIs available
- Low/middle-income countries: Limited to generic imatinib.[146]

10.2 Pricing and Affordability

Table 5 summarizes TKI costs.[147]

Table 5: TKI Annual Costs (USD).

TKI	US Average Wholesale Price	CostPlus/Generic Equivalent
Imatinib (generic)	$5,000-130,000	$500
Dasatinib (generic)	$4,000-7,000 (CostPlus)	$4,000-7,000
Dasatinib (brand)	$200,000+	-
Nilotinib	$200,000+	-
Bosutinib	$200,000+	-
Ponatinib	$313,000	-
Asciminib	$644,100 (T315I dose)	-

US pricing distortions result from pharmacy benefit managers, group purchasing organizations, and vertical integration.[148,149]

11. FUTURE DIRECTIONS

11.1 Increasing TFR Rates

- Optimize TKI combinations (TKI + interferon, TKI + venetoclax)
- Novel, more potent TKIs for faster DMR
- Immune-based strategies (NK cell enhancement, vaccination)[150]

11.2 Overcoming Resistance

- Next-generation STAMP inhibitors
- Combination approaches targeting BCR::ABL1-independent pathways
- Personalized therapy based on mutation profiling

11.3 Improving BP-CML Outcomes

- International collaborative trials (given rarity)
- Targeted therapies addressing epigenetic dysregulation
- Optimized transplant strategies.[151]

11.4 Predicting TFR Success

- ddPCR thresholds for TFR prediction
- Immune profiling (NK cells, Tregs, MDSCs)
- Transcript type and clonal dynamics.[152]

11.5 Optimizing Long-Term Safety

- OBD determination for all TKIs
- Cardiovascular risk mitigation strategies
- Quality of life monitoring.[153]

12. CONCLUSIONS

The molecular characterization of CML has established a paradigm for precision oncology. BCR::ABL1 TKIs achieve near-normal life expectancy for most patients, with TFR offering potential cure for those achieving sustained DMR. Six approved TKIs provide multiple therapeutic options, with selection guided by efficacy, toxicity profile, patient comorbidities, and cost.

Current challenges include overcoming TKI resistance (particularly T315I and compound mutations), improving BP-CML outcomes, increasing TFR rates, managing long-term cardiovascular toxicity, and ensuring global access to effective therapies. Emerging third-generation TKIs and combination strategies offer promise for addressing these challenges.

As CML prevalence continues to rise, lifelong management requires nuanced understanding of TKI selection, dose optimization, toxicity management, and TFR eligibility. Integration of molecular monitoring,

mutation testing, and emerging technologies (ddPCR, NGS) will further personalize therapy. Global collaboration remains essential to extend the benefits of TKI therapy to all patients worldwide.

Conflict of Interest Statement: The authors declare no conflicts of interest.

Funding: This work was supported by NCCP.

13. REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin., 2022; 72(1): 7-33.
2. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol, 2022; 97(9): 1236-56.
3. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 2012; 118(12): 3123-7.
4. Sasaki K, Haddad FG, Short NJ, et al. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer, 2023; 129(23): 3805-14.
5. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst., 2011; 103(7): 553-61.
6. Kantarjian H, Jabbour E, Cortes J. Chronic Myeloid Leukemia. In: Loscalzo J, Fauci A, Kasper D, et al., eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education, 2022.
7. Leukemia EiCM. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013; 121(22): 4439-42.
8. Hamid GA, Clinical hematology [2013]. https://doi.org/10.13140/RG.2.1.1477.1683
9. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973; 243(5405): 290-3.
10. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell., 1984; 36(1): 93-9.
11. Hamid GA (2015) Treatment Development of Chronic Myeloid Leukemia.J Develop Drugs, 4: e144. doi:10.4172/2329-6631.1000e144
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med., 2006; 355(23): 2408-17.
13. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med., 2017; 376(10): 917-27.
14. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia, 2016; 30(1): 48-56.
15. Abdul Hamid G (ed.) (2019) Advances in Hematologic Malignancies. IntechOpen. Available at: http://dx.doi.org/10.5772/intechopen.77785.
16. Soverini S, Mancini M, Bavaro L, et al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer, 2018; 17(1): 49.
17. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009; 16(5): 401-12.
18. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol, 2015; 33(35): 4210-8.
19. Mahon FX. Treatment-free remission in CML: who, how, and why? Hematology Am Soc Hematol Educ Program, 2017; 2017(1): 102-9.
20. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program, 2019; 2019(1): 433-42.
21. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood, 2000; 96(10): 3343-56.
22. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer, 2012; 12(8): 513-26.
23. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 1996; 88(7): 2375-84.
24. Abdul Hamid G. Target therapy and monitoring of chronic myeloid leukemia. World Journal of Pharmaceutical Research, 2015; 4(9): 391-405.
25. Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 2009; 114(11): 2232-5.
26. Hamid GA, Akrabi A. Aberrant antigenexpression in patients with acute leukemia. ECClin Med Case Report, 2019; 53–60.
27. Gong Z, Zhou T, Liu H, et al. Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. Br J Haematol, 2020; 189(5): e207-11.
28. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia, 1994; 8(1): 186-9.

29. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol, 2004; 5(1): 33-44.
30. Reckel S, Gehin C, Tardivon D, et al. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase. Nat Commun., 2017; 8(1): 2101.
31. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest, 2010; 120(7): 2254-64.
32. Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004; 18(2): 189-218.
33. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J., 1997; 16(20): 6151-61.
34. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL. J Biol Chem., 1999; 274(16): 11060-7.
35. Kirchner D, Duyster J, Ottmann O, et al. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol, 2003; 31(6): 504-11.
36. Hehlmann R. How I treat CML blast crisis. Blood, 2012; 120(4): 737-47.
37. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 2011; 118(26): 6760-8.
38. Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 2016; 127(22): 2742-50.
39. Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 2018; 132(9): 948-61.
40. Bidikian A, Kantarjian H, Jabbour E, et al. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J., 2022; 12(10).
41. Schonfeld L, Rinke J, Hinze A, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia, 2022; 36(9): 2242-9.
42. Ko TK, Javed A, Lee KL, et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020; 135(26): 2337-53.
43. Cortes JE, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood, 2012; 120(7): 1390-7.
44. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program, 2019; 2019(1): 433-42.
45. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013; 122(6): 872-84.
46. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow features and clinical findings in chronic myeloid leukemia—a comparative, multicenter, immunohistological and morphometric study on 614 patients. Leuk Lymphoma, 2000; 36(3-4): 295-308.
47. Senapati J, Sasaki K, Issa GC, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J., 2023; 13(1): 58.
48. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia, 2002; 16(1): 53-9.
49. Fabarius A, Kalmanti L, Dietz CT, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol, 2015; 94(12): 2015-24.
50. Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009; 114(24): 4939-43.
51. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood, 2005; 105(6): 2281-6.
52. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med., 2003; 349(15): 1423-32.
53. Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 2012; 26(10): 2172-5.
54. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 2020; 34(4): 966-84.
55. Colafligi G, Scalzulli E, Porrazzo M, et al. Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. Hematol Oncol, 2019; 37(5): 652-4.
56. Bernardi S, Malagola M, Zanaglio C, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med., 2019; 8(5): 2041-55.

57. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 2020; 34(4): 966-84.
58. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol, 2012; 30(3): 232-8.
59. Nazha A, Kantarjian H, Jain P, et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica, 2013; 98(11): 1686-8.
60. Hamid GA, Abdul-Rahman SA, Nasher S, HadiYA. Chronic Myeloid Leukemia in South Yemen.Int J Biopharm Sci., 2018; 1(2): 110.
61. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med., 2017; 376(10): 917-27.
62. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol, 2016; 34(20): 2333-40.
63. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012; 125(17): 2128-37.
64. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 2021; 35(2): 440-53.
65. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd Trial. Leukemia, 2016; 30(5): 1044-54.
66. Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia, 2022; 36(7): 1825-33.
67. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol, 2018; 36(3): 231-7.
68. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell., 2009; 16(5): 401-12.
69. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018; 132(4): 393-404.
70. Jabbour E, Apperley J, Cortes J, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia, 2024; 38(3): 475-81.
71. Schoepfer J, Jahnke W, Berellini G, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem., 2018; 61(18): 8120-35.
72. Hochhaus A, Wang J, Kim D-W, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med., 2024; 391(10): 885-98.
73. Hochhaus A, Rea D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia, 2023; 37(3): 617-26.
74. Kantarjian H, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol, 2023; 10(10): e860-4.
75. Kantarjian H, Branford S, Breccia M, et al. Are there new relevant therapeutic endpoints in the modern era of the BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia, 2024; 38(5): 947-50.
76. Kantarjian HM, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol, 2023; 10(10): e860-4.
77. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 2016; 30(8): 1648-71.
78. Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020; 34(8): 2138-49.
79. Kantarjian H, Paul S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol, 2022; 9(11): e854-61.
80. Corbaux P, Madani ME, Tod M, et al. Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective? J Clin Oncol, 2019; 37(15_suppl): 3060.
81. Haddad FG, Kantarjian H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw, 2024; 22(1): e237116.
82. Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2020; 126(1): 67-75.
83. Malagola M, Iurlo A, Buelli C, et al. The Italian Multicentric Randomized OPTKIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and

Quality of Life Monitoring After Completing the Treatment Plan. Clin Lymphoma Myeloma Leuk, 2024; 24(5): 323-31.
84. Breccia M, Olimpieri PP, Olimpieri O, et al. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer Med., 2020; 9(12): 4160-5.
85. Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res., 2014; 38(1): 10-20.
86. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 2007; 110(7): 2242-9.
87. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 2017; 543(7647): 733-7.
88. Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol, 2022; 15(1): 113.
89. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell., 2014; 26(3): 428-42.
90. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 2000; 96(3): 1070-9.
91. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 2007; 110(12): 4064-72.
92. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2008; 112(5): 2024-7.
93. Zhao H, Deininger MW. Declaration of Bcr-Abl1 independence. Leukemia, 2020; 34(11): 2827-36.
94. Soverini S, Bavaro L, De Benedittis C, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020; 135(8): 534-41.
95. Soverini S, De Benedittis C, Mancini M, Martinelli G. Best practices in chronic myeloid leukemia monitoring and management. Oncologist, 2016; 21(5): 626-33.
96. Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood, 2009; 114(20): 4361-8.
97. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR-ABL1 tyrosine kinase inhibitors. Am J Hematol, 2023; 98(4): 658-65.
98. Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol, 2022; 15(1): 113.
99. Jiang Q, Li Z, Zhang G, et al. Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study. Blood, 2023; 142(Supplement 1): 869.
100. Jabbour E, Oehler VG, Koller PB, et al. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol, 2025; 11(1): 28-35.
101. Jiang Q, Zhang Y, Wang Q, et al. Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study. Blood, 2023; 142(Supplement 1): 867.
102. Weiming L, Zhang Y, Zhu H, et al. Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML). Blood, 2024; 144: 480.
103. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010; 115(10): 1880-5.
104. Haddad FG, Sasaki K, Bidikian A, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol, 2023; 98(10): 1619-26.
105. Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood, 2015; 125(21): 3230-5.
106. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 2010; 11(11): 1029-35.
107. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol, 2017; 35(3): 298-305.
108. Haddad FG, Sasaki K, Issa GC, et al. Treatment-free remission in patients with chronic myeloid leukemia

following the discontinuation of tyrosine kinase inhibitors. Am J Hematol, 2022; 97(7): 856-64.
109. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol, 2018; 19(6): 747-57.
110. Farhat A, Kantarjian HM, Haddad FG, et al. Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia. Blood, 2024; 144(Supplement 1): 6605.
111. Lee S, Mun Y-C, Kim H, et al. A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Blood, 2024; 144(Supplement 1): 1779.
112. Mahon F-X, Pfirrmann M, Dulucq S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Blood, 2020; 136(Supplement 1): 45-6.
113. Ilander M, Olsson-Stromberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia, 2017; 31(5): 1108-16.
114. Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol, 2014; 32(25): 2821-3.
115. Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol, 2020; 7(3): e218-25.
116. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood, 2017; 129(7): 846-54.
117. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma, 2020; 61(3): 650-9.
118. Ross DM, Masszi T, Gomez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol, 2018; 144(5): 945-54.
119. Massimo Breccia FC, Piciocchi A, Abruzzese E, et al. Sustenim Trial: Sustained Deep Molecular Response And Tfr Rate In The Long-Term Follow-Up. EHA Library, 2024; 422275.
120. Rea D, Ame S, Berger M, et al. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice. Haematologica, 2018; 103(5): 875-83.
121. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol, 2014; 32(5): 424-30.
122. Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica, 2016; 101(6): 717-23.
123. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 2013; 122(4): 515-22.
124. Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia, 2023; 37(1): 5-17.
125. Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR-ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol, 2023; 98(9): 1350-3.
126. Berman E, Shah NP, Deninger M, et al. CML and the WHO: Why? J Clin Oncol, 2024; 42(9): 984-6.
127. Hornak T, Mayer J, Cicatkova P, et al. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. Am J Hematol, 2024; 99(4): 763-6.
128. Senapati J, Ravandi F, DiNardo CD, et al. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML). Blood, 2022; 140(Supplement 1): 3880-2.
129. Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol, 2022; 9(2): e121-32.
130. Karrar O, Jabbour E, Senapati J, et al. A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse. Blood, 2024; 144(Supplement 1): 3156.
131. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia, 2013; 27(6): 1316-21.

132. Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol, 2016; 17(5): 612-21.
133. Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood, 2019; 133(14): 1597-606.
134. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol, 2016; 34(20): 2333-40.
135. Savani S, Pawa A, Mahadevia H, Master SR. Cardiovascular complications associated with asciminib use: A retrospective analysis. J Clin Oncol, 2024; 42(16_suppl): Abstract 6563.
136. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 2016; 30(8): 1648-71.
137. Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, et al. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev., 2022; 56: 100968.
138. Shah NP, Bhatia R, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2024; 22(1): 43-69.
139. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 2007; 110(12): 4005-11.
140. Lasica M, Willcox A, Burbury K, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma, 2019; 60(7): 1796-802.
141. Russo D, Malagola M, Skert C, et al. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J., 2015; 5(9): e347.
142. Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood, 2016; 127(4): 392-9.
143. Weiming L, Danyu W, Jingming G, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia, 2020; 34: 1799-804.
144. Rea D, Mauro MJ, Cortes JE, et al. COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (icmlf) CML and COVID-19 (CANDID) Study. Blood, 2020; 136(Suppl 1): 46-7.
145. Kantarjian H, Jabbour E, Cortes J. Chronic Myeloid Leukemia. In: Loscalzo J, Fauci A, Kasper D, et al., eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education, 2022.
146. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program, 2019; 2019(1): 433-42.
147. Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc., 2015; 90(4): 500-4.
148. Rebecca Robbins RA. The Opaque Industry Secretly Inflating Prices for Prescription Drugs. New York Times. June 21, 2024.
149. Rooke-Ley H, Shah S, Brown ECF. Medicare Advantage and Consolidation's New Frontier - The Danger of UnitedHealthcare for All. N Engl J Med., 2024; 391(10): 885-98.
150. Hughes A, Clarson J, White DL, et al. Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation. Blood, 2016; 128(22): 1122.
151. Daver N, Benton CB, Ravandi F, et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) for treatment of naïve higher risk myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Blood, 2019; 134(Suppl 1): 568.
152. Nicolini FE, Dulucq S, Boureau L, et al. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Clin Cancer Res., 2019; 25(22): 6606-13.
153. Chen Y, Xu N, Yang Y, et al. Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia. Cancer Med., 2023; 12(16): 17239-52.